Two studies from the Immunology group on autoimmunity and hematopoietic stem cells show promising therapeutic potential

The first study, published in Nanomedicine: Nanotechnology, Biology and Medicine, seeks a strategy to safely and definitevely restore self-tolerance in autoimmune diseases; the second, in Archivum Immunologiae et Therapiae Experimentalis, bets on making the most of umbilical cord blood cells, key against hematological diseases

Two IGTP projects, financed with 1.6 million euros by the European Commission

The European Commission has granted two projects to the IGTP within the HORIZON programme, which add up to a total of 1,670,346 euros in funding and deal with the preclinical development of immunotherapies.

In vitro development of a new personalized therapy for patients with neurofibromatosis type 2

Researchers from the Clinical Genomics group of the Germans Trias i Pujol Research Institute (IGTP) and the Genetics Service of the Germans Trias Hospital (HUGTiP) have developed a new in vitro therapy to recover part of the function encoded by the gene NF2, which, when altered, induces the development of neurofibromatosis type 2. The study has been published in the prestigious journal Molecular Therapy Nucleic Acids.

A study of more than 750 healthcare professionals confirms that antibodies persist 17 months after having suffered from COVID-19

• Research has also confirmed that people who suffered from the disease in a serious way generate more antibodies than those who had moderate and mild effects.
• The results of this study show significant differences in the generation of antibodies between men and women on day 30 of infection and for all antibodies measured.
• This is one of the largest studies carried out to date in Catalonia, both in terms of the volume of participants and the length of follow-up.

A project that develops a new immunotherapy based on a monoclonal antibody to treat cancer is one of the three initiatives chosen by CaixaResearch Consolidate

A project that develops a monoclonal antibody for cancer treatment, led by the Innate Immunity Research Group at the IGTP, is one of the three selected in the CaixaResearch Consolidate call of “la Caixa” Foundation to cutting-edge innovative biomedical projects.

Study Sets the Basis for Identifying Biomarkers of Latent Malaria Vivax Infections

Using a mouse model, the research team characterized the protein profile of small vesicles secreted by liver cells, where the latent form of the parasite hides.

A diet rich in plant-based omega-3 is associated with better outcomes in heart failure patients

Higher levels of plant-based omega-3 fats reduce the risk of death and hospital admission in people with heart failure. This is according to a joint study by researchers at Germans Trias i Pujol Hospital and Research Institute and the Hospital del Mar Medical Research Institute, published in the Journal of the American College of Cardiology, involving the follow-up of almost a thousand patients.

Research impulse into hepatoblastoma, the main childhood liver cancer

A collaborative CIBER project will boost hepatoblastoma (HB) research to identify new therapeutic targets that will allow strategies to be developed to improve the prognosis of those children who currently do not survive the disease. The project coordinated by Carolina Armengol, principal CIBEREHD researcher at the Germans Trias i Pujol Research Institute (IGTP) is a collaboration between 5 CIBER groups belonging to the Hepatic and Digestive Diseases area (CIBEREHD) and the Cancer area (CIBERONC).

Less women in scientific production, a reality of the COVID-19 lockdown

A study promoted by the "Women in Science" working group of the Can Ruti Campus, has shown that, from July to October 2020, scientific production was more linked to men. Women, on the other hand, developed a greater number of scientific activities perceived as altruistic.

A study of patients with ovarian cancer highlights the need to identify the mechanisms of resistance to PARP inhibitors to find effective therapies for this tumour

Retreatment with platinum-based chemotherapy as a therapy for relapsed ovarian cancer after progression to PARP inhibitors shows different results for patients with BRCA-mutated and BRCA wild-type tumours.